Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes

Toxicol Sci. 2011 Sep;123(1):281-9. doi: 10.1093/toxsci/kfr158. Epub 2011 Jun 20.


Improved in vitro systems for predicting drug-induced toxicity are needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition. One unmet need is an early screen for cardiotoxicity, which accounts for about one third of safety-based withdrawn pharmaceuticals. Herein, the first published report of a high-throughput functional assay employing a monolayer of beating human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) is described, detailing a model that accurately detects drug-induced cardiac abnormalities. Using 96-well plates with interdigitated electrode arrays that assess impedance, the rhythmic, synchronous contractions of the iPSC-CMs were detected. Treatment of the iPSC-CMs with 28 different compounds with known cardiac effects resulted in compound-specific changes in the beat rate and/or the amplitude of the impedance measurement. Changes in impedance for the compounds tested were comparable with the results from a related technology, electric field potential assessment obtained from microelectrode arrays. Using the results from the set of compounds, an index of drug-induced arrhythmias was calculated, enabling the determination of a drug's proarrhythmic potential. This system of interrogating human cardiac function in vitro opens new opportunities for predicting cardiac toxicity and studying cardiac biology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arrhythmias, Cardiac / chemically induced*
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Drug Discovery / methods
  • Drug Evaluation, Preclinical / adverse effects*
  • Humans
  • Myocytes, Cardiac / drug effects*
  • Pharmaceutical Preparations
  • Pluripotent Stem Cells / drug effects*


  • Pharmaceutical Preparations